Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2015 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Total Non-Current Liabilities came in at $143000.0 in Q1 2026, down 71.57% year-on-year from $503000.0 in Q1 2025, and down 37.55% quarter-over-quarter from $229000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $143000.0 for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 71.57% year-over-year to $143000.0 in Q1 2026; TTM through Mar 2026 was $143000.0, a 71.57% decrease from a year earlier, with the FY2025 full-year figure at $229000.0, down 61.38% from the prior year.
- Total Non-Current Liabilities fell to $143000.0 in Q1 2026 per CRVS's latest filing, from $229000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.0 million in Q2 2022 and bottomed at $143000.0 in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $610000.0 (2024), against an average of $619875.0.
- Across the five-year window, Total Non-Current Liabilities surged 838.1% in 2022 and slumped 71.57% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $985000.0 in 2022, then tumbled by 34.21% to $648000.0 in 2023, then dropped by 8.49% to $593000.0 in 2024, then slumped by 61.38% to $229000.0 in 2025, then slumped by 37.55% to $143000.0 in 2026.
- Per Business Quant, the three latest CRVS Total Non-Current Liabilities figures stand at $143000.0 (Q1 2026), $229000.0 (Q4 2025), and $321000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | 143,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143,000.00 |
| Dec 31, 2025 | 229,000.00 |
| Sep 30, 2025 | 321,000.00 |
| Jun 30, 2025 | 414,000.00 |
| Mar 31, 2025 | 503,000.00 |
| Dec 31, 2024 | 593,000.00 |
| Sep 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 531,000.00 |
| Mar 31, 2024 | 595,000.00 |
| Dec 31, 2023 | 648,000.00 |
| Sep 30, 2023 | 686,000.00 |
| Jun 30, 2023 | 773,000.00 |
| Mar 31, 2023 | 903,000.00 |
| Dec 31, 2022 | 985,000.00 |
| Sep 30, 2022 | 945,000.00 |
| Jun 30, 2022 | 1.02 Mn |
| Dec 31, 2021 | 105,000.00 |
| Dec 31, 2018 | 7.03 Mn |
| Sep 30, 2018 | 7.75 Mn |
| Jun 30, 2018 | 9.78 Mn |